Prognostic significance of ras/p21 alterations in human ovarian cancer

British Journal of Cancer

Volumn 75, Issue 10, 1997, Pages 1547-1553

  Scambia, G ^a   Masciullo, V ^a   Benedetti Panici, P ^a   Marone, M ^a   Ferrandina, G ^a   Todaro, N ^a   Bellacosa, A ^a   Jain, S K ^a   Neri, G ^a   Piffanelli, A ^b   Mancuso, S ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

Author keywords

K ras; Mutation; Ovarian carcinoma; Overexpression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN P21; RAS PROTEIN;

ARTICLE; ASCITES; CANCER SURVIVAL; CONTROLLED STUDY; DNA HYBRIDIZATION; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; METASTASIS; MULTIVARIATE ANALYSIS; OMENTUM; ONCOGENE K RAS; OVARY; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; TUMOR GROWTH;

EID: 8244242527     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.264     Document Type: Article

References (48)

1. Bartlett JMS, Langdon SP, Simpson BJB, Stewart M, Katsaros D, Sismondi P, Love S, Scott WN, Williams ARW, Lesseis AM, MacLeod KG, Smyth JF and Miller WR (1996) The prognostic value of epidermal growth factor receptor mRna expression in primary ovarian cancer. Br J Cancer 73: 301-306
2. Benedetti Panici P, Scambia G, Greggi S, Salerno G, Cento R and Mancuso S (1990) Doxorubicin and cyclophosphamide, alternate with bleomycin and mytomycin C as a second line regimen in advanced ovarian carcinoma resistant to cisplatin based chemotherapy. Oncology 47: 296-298
3. Benedetti Panici P, Scambia G, Baiocchi G, Greggi S and Mancuso S (1991) Technique and feasibility of systematic paraaortic and pelvic lymphadenectomy for gynecological malignancies: a prospective study. Int J Gynecol Cancer 1: 133-140
4. Benedetti Panici P, Greggi S, Scambia G, Baiocchi G, Lomonaco M, Conti G and Mancuso S (1993) Efficacy and toxicity of very high-dose cisplatin in advanced ovarian carcinoma: 4-year survival analysis and neurological follow-up. Int J Gynecol Cancer 3: 44-53
5. Bland KI, Konstadoulakis MM, Vezeridis MP and Wanebo HJ (1995) Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos. and p53 as prognostic discriminants for breast carcinomas. Ann Surg 221: 706-720
6. Boltz EM, Kefford RF, Leary JA, Houghton CR and Friedlander ML (1989) Amplification of c-ras-ki oncogene in human ovarian tumours. Int J Cancer 43: 428-430
7. Bos JL (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689
8. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye-binding. Anal Biochem 72: 248-256
9. Caulin C, Lopex-Barcons L, Gonzales-Garrigues M, Navarro P, Lozano E, Rodrigo I, Gumallo C, Cano A, Fabra A and Quintanilla M ( 1996) Suppression of the metastatic phenotype of a mouse skin carcinoma cell line independent of E-cadherin expression and correlated with reduced H-ras oncogene products. Mol Carcinog 15: 104-114
10. Copeland LJ and Gershenson DM (1986) Ovarian cancer recurrences in patients with no macroscopic tumor at second-look laparotomy. Obstet Gynecol 68: 873-874
11. Cox DR (1972) Regression models and life tables. J R Stat Soc 34: 197-220
12. Cuatrecasas M, Matias-Guiu X and Prat J (1996) Synchronous mucinous tumors of the appendix and the ovary associated with pseudomyxoma peritonei. A clinicopathologic study of six cases with comparative analysis of Kras mutations. Am J Surg Pathol 20: 739-746
13. Dickson RB, Kasid A, Huff KK, Bates SH, Knabbe C, Bronzert D, Gelmann EP and Lipmann ME (1987) Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17-β-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837-841
14. Egan SH, McClarty GA, Jarolim L, Wright JA, Spiro I, Hager G and Greenberg AH (1987) Expression of Hras correlates with metastatic potential: evidence for direct regulation of the metastatic phenotype in 10 T1/2 and NIH 3T3 cells. Mol Cell Biol 7: 830-837
15. Egan SH, Broere JJ, Jarolim L, Wright JA and Greenberg AH (1989) Coregulation of metastatic and transforming activity of normal and mutant ras genes. Int J Cancer 43: 443-448
16. Enomoto T, Inoue M, Perantoni AO, Terakawa N, Tanizawa O and Rice JM (1990) K-ras activation in neoplasms of human female reproductive tract. Cancer Res 50: 6139-6145
17. Enomoto T, Weghorst CM, Inoue M, Tanizawa O and Rice JM (1991) K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-785
18. Forrester K, Almoguera C, Han K, Grizzle WE and Perucho M (1987) Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 327: 298-303
19. Garbisa S, Pozzatti R, Muschel RJ, Saffiotti U, Ballin M, Goldfarb RH, Khoury G and Liotta LA (1987) Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela. Cancer Res 47: 1523-1528
20. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C and Sismondi P (1994) Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 14(3B): 1441-1450
21. Gibbs JB, Oliff A and Kohl NH (1994) Farnesyltransferase inhibitors: ras research yields a potential cancer therapeutic. Cell 77: 175-178
22. Hanley JA and McNeil BJ ( 1982) The meaning and the use of the area under a receiver operating characteristic (ROC) curve. Radiology 143: 29-36
23. Kaplan E and Meier P (1958) Non parametric estimation from incomplete observation. J Am Stat Assoc 53: 457-481
24. Katsaros D, Theillet C, Zola P, Louason G, Sanfilippo B, Isaia E, Arisio R, Giardina G and Sismondi P (1995) Concurrent abnormal expression of Erb-b2, myc and ras genes is associated with poor outcome of ovarian cancer patients. Anticancer Res 15: 1501-1510
25. Kohl NE, Wilson FR, Mosser SD, Giuliani E, DeSolms SJ, Conner MW, Anthony NJ, Holtz WJ, Gomez RP, Lee TJ, Smith RL, Graham SL, Hartman GD Gibbs JB and Oliff A (1994) Protein farnesyltransferase inhibitors block the growth of ras dependent tumors in nude mice. Proc Natl Acad Sci USA 91: 9141-9145
26. Kuzumaki N, Oda A, Yamagiwa S, Taniguchi N, Kobayashi H, and Oikawa T (1986) Establishment of four mouse hybridoma cell lines producing monoclonal antibodies reactive with ras oncogene product p21. J Natl Cancer Inst 77: 1273-1279
27. Liu E, Hjelle B, Morgan R, Hecht F and Bishop M (1987) Mutation of the Kirsten-ras proto-oneogene in humun preleukemia. Nature 300; 186-188
28. Mantel N (1966) Evaluation of survival data and two new rank order statistics arising in its considerations. Cancer Chemother Rep 50: 163-170
29. Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S and Garrett CT (1992) Clinical implications of Kras mutations in malignant epithelial tumors of the endometrium. Canter Res 52: 2777-2781
30. Mok SC-H, Bell DA, Knapp RC, Fishbaugh PM, Welch WR, Muto MG, Berkowitz RS and Tsao SW (1993) Mutation of K-ras protooncogene in human ovarian epithelial tumors of borderline malignancy. Cancer Res 53: 1489-1492
31. O'Brien TJ, Bannon GA, Bard DS, Hardin JW and Quirk JG (1989) Expression of the ras oncogene in gynecologic tumors. Am J Obstet Gynecol 160: 344-352
32. Robinson A, Williams ARW, Piris J, Spandidos DA and Wyllie AH (1986) Evaluation of a monoclonal antibody to ras peptide, RAP-5, claimed to bind preferentially to cells of infiltrating carcinomas. Br J Cancer 54: 877-883
33. Rodenburg CJ, Koelma IA, Nap M and Jan Fleuren G (1988) Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Arch Pathol Lab Med 112: 151-154
34. Rosell R, Li S, Skacel Z, Mate JL, Maestro J, Canela M, Tolosa E, Armengol P. Barnadas A and Ariza A (1993) Prognostic impact of mutated Kras gene in surgically resected non-small cell lung cancer patients. Oncogene 8: 2407-2412
35. Sambrook J, Fritsch EF and Maniatis T (1989) Molecular Cloning Vol. 2, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY 9.16-9.18
36. ras.GTP in response to stimulation with epidermal growth factor and oncogene products with tyrosine kinase activitv. Proc. Natl Acad Sci USA 87: 7926-7929
37. Scanibia G, Benedetti Panici P, Battaglia F, Ferrandina G. Baiocchi G, Greggi S, De Vincenzo R and Mancuso S (1992) Significance ol epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol 10: 529-535
38. Scanibia G, Catozzi L, Benedetti Panici P, Ferrandina G, Coronetta F, Barozzi R, Baiocchi G, Uccelli L, Piffanelli A and Mancuso S (1993a) Expression of ras oncogene p21 protein in normal and neoplastic ovarian tissues; correlation with histopathologic features and receptors for estrogen, progesterone and epidermal growth factor. Am J Obstet Gynecol 168: 71-78
39. Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Buiocchi G, Di Stefano P, Tinari N, Coronetta F, Piantelli M, Natali P, Iacobelli S and Mancuso S (1993b) Expression of HER-2/neu oncoprotein, DNA ploidy and S-phase fraction in advanced ovarian cancer. Int J Gynecol Cancer 3: 271-278
40. Scambia G, Benedetti Panici P, Ferrandina G, Distefano M, Romanini ME, Fagotti A and Mancuso S (1995) Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72: 361-366
41. Scambia G, Ferrandina G, Marone M, Benedetti Panici P, Giannitelli C, Piantelli M, Leone A and Mancuso S (1996) NM 23 in ovarian cancer: correlation with clinical outcome and other clinicopathological and biochemical prognostic factors. J Clin Oncol 14: 334-342
42. Slamon DJ, De Kernion JB, Verma IM and Cline MJ (1984) Expression of cellular oncogenes in human malignancies. Science 224: 256-262
43. Teneriello MG, Ebina M, Linnoila RI, Henry M, Nash JD, Park RC and Birrer MJ (1993) p53 and Ki-ras mutations in epithelial ovarian neoplasms. Cancer Res 53: 3103-3108
44. Thorgeirsson UP, Turpeenniemi-Hujanen T, Williams JE, Westin EH, Heilman CA, Talmadge JE and Liotta LA (1985) NIH/3T3 cells transfected with human tumor DNA containing activated ras oncogenes express the metastic phenotype in nude mice. Mol Cell Biol 5: 259-262
45. Van't Veer LJ, Hermens R, Van Den Berg-Bakker LAM, Cheng NC, Fleuren GJ, Bos JL, Cleton FJ and Schrier PI (1988) Ras oncogene activation in human ovarian carcinoma. Oncogene 2: 157-165
46. Wood WI, Gitschier J, Lasky LA and Lawn RM (1985) Base composition-independent hybridization in tetramethylammonium chloride: a method for oligonucleotide screening of highly complex gene libraries. Proc Natl Acad Sci 82: 1585-1588
47. World Health Organisation (1979) WHO handbook for reporting results of Cancer Treatment. Geneva, Switzerland. WHO 48: 16-21
48. Yaginuma Y, Yamashita K, Kuzumaki N, Fujita M and Shimizu T (1992) Ras oncogene product p21 expression and prognosis of human ovarian tumors. Gynecol Oncol 46: 45-50